Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

About Benign Prostatic Hyperplasia Drugs

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

Technavio's analysts forecast the global benign prostatic hyperplasia drugs market to grow at a CAGR of 7.07% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global benign prostatic hyperplasia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, Global Benign Prostatic Hyperplasia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi

Other Prominent Vendors

• ADC Therapeutics
• Advaxis
• Agennix
• ANI Pharmaceuticals
• Bayer HealthCare
• BHR Pharma
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Dendreon (Valeant Pharmaceuticals)
• Eisai
• Endo Pharmaceuticals
• Ferring
• Foresee Pharmaceuticals
• Io Therapeutics
• LIDDS
• Madrigal Pharmaceuticals
• Merck
• Novartis
• Nymox Pharmaceutical
• Spectrum Pharmaceuticals
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Urologix

Market driver

• Growing geriatric male population.
• For a full, detailed list, view our report

Market challenge

• Availability of minimally invasive surgery as a drug replacement.
• For a full, detailed list, view our report

Market trend

• Advancements in early-stage diagnosis through new diagnostic methods.
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

• Market outline

PART 05: BPH diagnostics

• Overview

PART 06: Pipeline landscape

PART 07: Market landscape

• Market overview
• Five forces analysis

PART 08: Market segmentation by MOA

• Alpha-blockers
• 5-ARIs
• PDE-5 inhibitors
• Others

PART 09: Geographical segmentation

• BPH drugs market in Americas
• BPH drugs market in EMEA
• BPH drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

• Market drivers
• Market challenges

PART 12: Market trends

• Advancements in early-stage diagnosis through new diagnostic methods
• Growing demand for MRI and ultrasound-guided prostate biopsy procedures
• Growing focus toward new MOA

PART 13: Vendor landscape

• Competitive scenario

PART 14: Key vendor analysis

• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi
• Other prominent vendors

PART 15: Appendix

• List of abbreviations

List of Exhibits

• Exhibit 01: Risk factors of prostate gland enlargement
• Exhibit 02: Difference between prostate cancer and BPH
• Exhibit 03: Pipeline analysis
• Exhibit 04: Pipeline landscape
• Exhibit 05: Global BPH drugs market snapshot
• Exhibit 06: Global BPH drugs market 2016-2021 ($ millions)
• Exhibit 07: Five forces analysis
• Exhibit 08: Market segmentation by MOA 2016
• Exhibit 09: Global BPH alpha-blockers drugs market 2016-2021 ($ millions)
• Exhibit 10: Global BPH 5-ARIs drugs market 2016-2021 ($ millions)
• Exhibit 11: Global BPH PDE-5 inhibitors drugs market 2016-2021 ($ millions)
• Exhibit 12: Segmentation of global BPH drugs market based on geography 2016 and 2021 (%)
• Exhibit 13: Global BPH drugs market revenue by geography 2016-2021 ($ millions)
• Exhibit 14: Market scenario in Americas
• Exhibit 15: BPH drugs market in Americas 2016-2021 ($ millions)
• Exhibit 16: Market scenario in EMEA
• Exhibit 17: BPH drugs market in EMEA 2016-2021 ($ millions)
• Exhibit 18: Market scenario in APAC
• Exhibit 19: BPH drugs market in APAC 2016-2021 ($ millions)
• Exhibit 20: Percentage of potential population for BPH among people with 65+ years 2014 and 2050
• Exhibit 21: Prominent side effects of BPH medication
• Exhibit 22: Impact of patent loss on AVODART 2014-2015 (GBP millions)
• Exhibit 23: New advancements in diagnosis of BPH
• Exhibit 24: Competitive structure analysis of global BPH drugs market 2016
• Exhibit 25: Competitive analysis of global BPH drugs market
• Exhibit 26: Astellas Pharma: Strength assessment
• Exhibit 27: Astellas Pharma: Strategy assessment
• Exhibit 28: Astellas Pharma: Opportunity assessment
• Exhibit 29: Eli Lilly: Key highlights
• Exhibit 30: Eli Lilly: Strength assessment
• Exhibit 31: Eli Lilly: Strategy assessment
• Exhibit 32: Eli Lilly: Opportunity assessment
• Exhibit 33: GlaxoSmithKline: Strength assessment
• Exhibit 34: GlaxoSmithKline: Strategy assessment
• Exhibit 35: GlaxoSmithKline: Opportunity assessment
• Exhibit 36: Sanofi: Key highlights
• Exhibit 37: Sanofi: Strength assessment
• Exhibit 38: Sanofi: Strategy assessment
• Exhibit 39: Sanofi: Opportunity assessment